STOCK TITAN
  1. Home
  2. Sec-filings
  3. CDTX
  4. [Form 4] Cidara Therapeutics, Inc. Insider Trading Activity

Cidara Therapeutics (CDTX) insider reports option exercises, share sale

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Cidara Therapeutics reported insider stock transactions by its COO & CLO. On December 10, 2025, 15,041 common shares were withheld to cover taxes on restricted stock unit vesting at $219.6 per share. The officer exercised employee stock options to purchase 3,500 shares at $16.654 and 6,459 shares at $20.2, and sold 9,959 shares at $220.077 per share. Following these transactions, the officer directly owned 25,033 common shares, including 400 acquired through the employee stock purchase plan, and held 6,207 stock options, with all share amounts adjusted for a 1-for-20 reverse stock split effective April 24, 2024.

Positive

  • None.

Negative

  • None.
Insider Ward Shane
Role COO & CLO
Sold 9,959 shs ($2.19M)
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 3,500 $0.00 --
Exercise Employee Stock Option (right to buy) 6,459 $0.00 --
Tax Withholding Common Stock 15,041 $219.60 $3.30M
Exercise Common Stock 3,500 $16.654 $58K
Exercise Common Stock 6,459 $20.20 $130K
Sale Common Stock 9,959 $220.077 $2.19M
Holdings After Transaction: Employee Stock Option (right to buy) — 0 shares (Direct); Common Stock — 24,633 shares (Direct)
Footnotes (1)
  1. Shares withheld for taxes on RSU vesting. Includes 400 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP), representing 200 shares purchased on each of the following dates: May 20, 2025; and November 20, 2025. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022. The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ward Shane
(Last) (First) (Middle)
6310 NANCY RIDGE DRIVE
SUITE 101
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
COO & CLO
3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/10/2025 F 15,041(1) D $219.6 24,633 D
Common Stock 12/10/2025 M 3,500 A $16.654 28,133 D
Common Stock 12/10/2025 M 6,459 A $20.2 34,592 D
Common Stock 12/10/2025 S 9,959 D $220.077 25,033(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $16.654 12/10/2025 M 3,500 (3) 03/30/2032 Common Stock 3,500 $0 0(4) D
Employee Stock Option (right to buy) $20.2 12/10/2025 M 6,459 (5) 03/26/2033 Common Stock 6,459 $0 6,207(4) D
Explanation of Responses:
1. Shares withheld for taxes on RSU vesting.
2. Includes 400 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP), representing 200 shares purchased on each of the following dates: May 20, 2025; and November 20, 2025.
3. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022.
4. The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
5. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023.
Remarks:
/s/ Shane Ward 12/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock transactions did Cidara Therapeutics (CDTX) disclose in this filing?

The filing shows the COO & CLO had 15,041 shares withheld to cover taxes on RSU vesting, exercised options for 3,500 and 6,459 shares, and sold 9,959 common shares at $220.077 per share.

How many Cidara Therapeutics (CDTX) shares does the COO & CLO own after these transactions?

After the reported transactions, the COO & CLO directly owned 25,033 Cidara Therapeutics common shares, as stated in the filing.

What stock options were exercised in the Cidara Therapeutics (CDTX) Form 4?

The officer exercised employee stock options to buy 3,500 shares of common stock at an exercise price of $16.654 and 6,459 shares at $20.2 per share.

At what price were Cidara Therapeutics (CDTX) shares sold in this insider transaction?

The Form 4 reports a sale of 9,959 Cidara Therapeutics common shares at a price of $220.077 per share on December 10, 2025.

How many stock options does the Cidara Therapeutics COO & CLO hold after the Form 4 transactions?

Following the reported option exercises, the officer held 6,207 employee stock options, as disclosed in the derivative securities table.

What does the Cidara Therapeutics filing say about its reverse stock split?

The filing notes that the reported security amounts were adjusted to reflect a 1-for-20 reverse stock split effected on April 24, 2024.

What employee stock purchase plan (ESPP) shares are included in the COO & CLO's holdings at Cidara Therapeutics (CDTX)?

The reported 25,033 directly owned shares include 400 shares acquired under the ESPP, with 200 shares purchased on May 20, 2025 and 200 on November 20, 2025.